As per the research report, Global Gene Therapy Market is expected to reach the market valuation of US$ 20.9 billion by 2027 expanding at a reasonable CAGR of 29.7% during the forecast period (2021-2027) from US$ 3.5 billion in 2019. Gene therapy inserts genetic material into cells to compensate for abnormal genes or to make a beneficial protein. The increasing number of clinical trials that are underway and tremendous mergers, acquisitions, and venture capital investments in the gene-therapy sector make the future looks bright for such therapies. To date, approximately 2,600 gene therapy clinical studies have been completed, are ongoing, or have been approved globally. More than ever, the field of gene therapy seeks to identify a route to the clinic and the market. Approximately 20 gene therapies have now been licensed and over two thousand clinical trials of human gene therapy have been published globally. Such advancements generate great hope that debilitating rare and inherited disorders as well as incurable diseases can be treated.
For complete research, request for Sample of the report browse through – https://univdatos.com/request_form/form/352
According to the Alliance for Regenerative Medicine (ARM) Quarterly Regenerative Medicine Global Data Report for the first quarter of 2019, 372 gene therapy clinical trials were in progress as of the end of Q1. Remarkably, a margin (217 or 58%) were studies in Phase II, followed by Phase I (123 or 33%), and Phase III (32 or 9%). The number of gene therapy clinical trials edged up by 10 from the 362 recorded as of the end of 2018. Substantially, the number of clinical studies leaped 17% year-over-year from the 319 trials in development as of Q1 2018. Many of the clinical trials in gene therapy have been aimed at the treatment of cancer indications including lung, gynecological, skin, urological, neurological, and gastrointestinal tumors, as well as hematological malignancies and pediatric tumors. The International Agency for Research on Cancer estimates that worldwide, 1 in 5 people is intended to develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. These new evaluations indicate that approximately 50 million people are living within 5 years of a past cancer diagnosis. Aging populations worldwide and socio-economic risk factors remain among the primary influences driving this surge.
Biogen, BioMarin Pharmaceuticals, bluebird bio, Bristol Myers Squibb, Gilead Sciences, Novartis, Orchard Therapeutics, Regenxbio, Spark Therapeutics, and uniQure are some of the prominent players operating in the global gene therapy market. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Insights Presented in the Report
“Amongst vectors, Viral vectors segment holds the major share”
Based on the vector type, the market is fragmented into viral and non-viral vectors. The viral vectors dominated the market with a share of 88.6% in 2019 and are expected to maintain their dominance during the forecast period owing to the significant improvements in vector engineering, delivery, and safety.
“Amongst viral vectors, adeno-associated virus vectors are anticipated to dominate the market during the analyzed period”
Furthermore, the viral vector market is mainly bifurcated into the lentivirus, adeno-associated virus, retrovirus & gammaretrovirus, modified herpes simplex virus, and adenovirus. In 2019, adeno-associated virus sub-segment accounted for a maximum market revenue share of 34% and is expected to remain dominant during the analyzed period owing to the easy integration into the host genome, no viral genes, able to transduce cells not actively dividing, a wide range of host cells, and being non-inflammatory and non-pathogenic. However, the non-viral vector is anticipated to grow at the highest CAGR over the forecast period.
“Amongst gene type, antigen segment dominated the market during the forecast period”
Based on gene type, the market is mainly fragmented into antigen, cytokine, tumor suppressor, suicide, deficiency, receptor, and others. In 2019, the antigen segment accounted for a maximum market revenue share of 19.2% and is expected to remain dominant during the analyzed period.
“Amongst indication, oncology segment holds the major share”
Based on indication, the market is bifurcated into oncology, rare diseases, cardiovascular, neurology, infectious, and others. In 2019, the oncology segment accounted for the maximum market share with 48.6% and is expected to be the leading segment of the gene therapy market during the forecast period due to the increasing incidence of cancer cases.
“Amongst the delivery method, in-vivo segment dominated the market during the forecast period”
Based on the delivery method, the market is mainly disintegrated into in-vivo and ex-vivo. In 2019, in-vivo segment accounted for a maximum market revenue share of 87.5% and is expected to remain dominant during the analyzed period owing to the direct transfer of genes into patients.
“North America represents one of the largest markets of Gene Therapy market”
For a better understanding of the market dynamics of the gene therapy market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, Australia, South Korea, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of US$ 1.7 billion in 2019 owing to the high prevalence rate of cancer, presence of high disposable income, and increase in funding for R&D activities associated with gene therapy.
The Gene Therapy Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
- Do you want to pass your Networking Fundamentals exam? and looking for reliable Microsoft 98-366.Microsoft 98-366 Exam Study Material: Achieving a Professional.